Skip to content

TAD After Chemotherapy in Locally Advanced Breast Cancer

Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05763641
Enrollment
162
Registered
2023-03-10
Start date
2021-02-01
Completion date
2027-06-01
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Locally Advanced, Sentinel Lymph Node

Brief summary

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

Detailed description

The procedure will consist of marking the pathological lymph node with 1 clip before the start of neoadjuvant chemotherapy (NAC) and performing surgery after completing the NAC. The TAD will include the exeresis of the node marked with a clip, and of the sentinels marked with technetium and/or patent blue, seeking to obtain at least 3 lymph nodes. Subsequently, the axillary lymphadenectomy will be completed to identify the false negative rate. An initial analysis will be carried out with the first 30 cases, and if there are more than 2 false negative cases, it will be completed until 81 cases of TAD without associated disease are obtained.

Interventions

PROCEDURETarget Axillary Dissection

TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection

Sponsors

Hospital Universitari de Bellvitge
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Axillary lymph node metastasis proven by cytology * Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis) * Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria * Neoadjuvant chemotherapy

Exclusion criteria

* cN3 verified by imaging tests * N2 due to internal mammary involvement (N2b). * Tumors whose surrogate molecular subtype is luminal A. * Patients undergoing neoadjuvant endocrine therapy * Patients with local recurrences and metastatic tumors.

Design outcomes

Primary

MeasureTime frameDescription
TAD validation in locally advanced breast cancer3 yearsFalse negative rate when performing TAD after NAC

Secondary

MeasureTime frameDescription
Ultrasound validity to evaluate axillary response after NAC3 yearsFalse-negative and positive rates of axillary ultrasound after NAC to assess lymph node response
MRI validity to evaluate axillary response after NAC3 yearsFalse-negative and positive rates of axillary MRI after NAC to asses lymph node response

Countries

Spain

Contacts

CONTACTAmparo García-Tejedor, MDPhD
agarciat@bellvitgehospital.cat0034-932607702
PRINCIPAL_INVESTIGATORamparo Garcia-Tejedor, MDPhD

Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026